Skip to main navigation

Back

Contact Revance
Login

Menu

Aesthetics
Back Aesthetics
Visit Site
Therapeutics
Back Therapeutics
Investors
Back Investors
LATEST NEWS
Our Latest

December 22, 2020

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection All News
Company
Back Company
OUR LATEST
Our Latest

December 22, 2020

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Our Latest
News
Careers
Back Careers

facebook
instagram
twitter
linkedin

1222 Demonbreun St
Suite 2000
Nashville, TN 37203

+1 (510) 742-3400

Contact Revance
Login

© Copyright 2021

All Rights Reserved

Breadcrumb

Home
Investors
Press releases

Press Releases

Press Releases

Items Per Page

Year

April 6, 2021

Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

April 1, 2021

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

March 22, 2021

Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021

February 24, 2021

Revance to Participate in Upcoming Virtual Healthcare Conferences

February 23, 2021

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 22, 2021

Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

February 22, 2021

Revance Reports Fourth Quarter and Full Year 2020 Financial Results

February 22, 2021

Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors

February 12, 2021

Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021

January 25, 2021

Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 245

Investor Relations

Investor Relations
Press Releases
Events & Presentations
- Events
- Presentations and Corporate Materials
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investor FAQs
Contact Us

image description

Revance - Shareholder Tools

Print Page
Printed Materials
Email Alerts
Download Library
RSS News Feeds
Share
Search

Keep up with Revance

Subscribe

1222 Demonbreun St
Suite 2000
Nashville, TN 37203

+1 (510) 742-3400

facebook
instagram
twitter
linkedin

Aesthetics

Overview
RHA®
HintMD
Neuromodulator
Neuromodulator Uses
Clinical Highlights

Therapeutics

Overview
Cervical Dystonia
Upper Limb Spasticity
Plantar Fasciitis
Clinical Highlights

Investors

Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investor FAQ
Contact Us

Company

Overview
About Revance
Leadership Team
Board of Directors
Partnerships
Investigator Sponsored Trials
Medical Education Grants
Sustainability
Contact Revance

News

All News
In the News
Our Latest

Careers

Overview
Career Opportunities
Culture
Benefits & Perks

© Copyright 2021
All Rights Reserved
Terms of Use
Privacy Policy
Corporate Social Media Community Guidelines

Facebook
LinkedIn